AFX2
Report
- Report Number
- 3011063223-2024-00099
- Event Type
- Injury
- Date Received
- July 1, 2024
- Date of Event
- June 10, 2024
- Report Date
- June 10, 2024
- Manufacturer
- ENDOLOGIX
- Product Code
- MIH
- UDI-DI
- 00818009014726
- PMA / PMN Number
- P040002
- Removal / Correction Number
- Z-0007-2019
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NE, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
THE DEVICE INVOLVED IN THIS EVENT WAS NOT RETURNED FOR EVALUATION. PATIENT MEDICAL RECORDS AND IMAGING STUDIES WILL BE REQUESTED FOR FURTHER EVALUATION BY THE CLINICAL SPECIALIST. IF ADDITIONAL INFORMATION PERTINENT TO THE INCIDENT IS OBTAINED, A FOLLOW-UP REPORT WILL BE SUBMITTED. DEVICE ITERATION IS AFX2.
THE REPORTED ADVERSE EVENT/INCIDENT WAS INVESTIGATED IN ACCORDANCE WITH ENDOLOGIX OPERATING PROCEDURES AND WORK INSTRUCTIONS. WHERE POSSIBLE, IT IS ENDOLOGIX'S PRACTICE TO MAKE AT LEAST THREE GOOD-FAITH EFFORTS TO RETRIEVE A DEVICE RELATED TO A REPORTED ADVERSE EVENT/INCIDENT, AS WELL AS THE CORRESPONDING MEDICAL RECORDS AND MEDICAL IMAGING. AN EVALUATION OF THE MANUFACTURING RECORD WAS COMPLETED. A REVIEW OF THE PART NUMBER/LOT NUMBER COMBINATION NECESSARY FOR DEVICE IDENTIFICATION CONFIRMED THAT THE DEVICE WAS PROPERLY MANUFACTURED AND RELEASED IN ACCORDANCE WITH THE DEVICE MASTER RECORD. THE REVIEW CONFIRMS THAT NO MANUFACTURING OR PROCESSING NON-CONFORMITIES WERE IDENTIFIED THAT WOULD HAVE CONTRIBUTED TO THE REPORTED ADVERSE EVENT/INCIDENT. THE DEVICE WAS NOT RETURNED TO ENDOLOGIX FOR EVALUATION AS IT REMAINS IMPLANTED. A CLINICAL EVALUATION OF THE ADVERSE EVENT/INCIDENT WAS COMPLETED. AN EXAMINATION OF MEDICAL RECORDS AND/OR MEDICAL IMAGING RECEIVED BY ENDOLOGIX CONFIRMED THE AFX2, TYPE IIIB ENDOLEAK, AND ADDITIONAL ENDOVASCULAR PROCEDURE COMPLAINTS. THESE FINDINGS ARE CONSISTENT WITH THE REPORTED ADVERSE EVENT/INCIDENT. THE CLINICAL EVALUATION ALSO REVEALED REASONABLE EVIDENCE SUGGESTING AN ANEURYSM ENLARGEMENT OF 5 MM AND A TYPE II ENDOLEAK FROM THE LUMBAR ARTERY. PROCEDURE-RELATED HARMS, DEVICE, USER, PROCEDURE, OR ANATOMY-RELATEDNESS OF THIS COMPLAINT COULD NOT BE DETERMINED WITH THE MEDICAL RECORDS AVAILABLE FOR REVIEW. THE INITIAL PROCEDURE WAS PERFORMED OUTSIDE THE INDICATIONS FOR USE (OFF-LABEL) DUE TO THE USE OF ADJUNCTIVE DEVICES (OVATION LIMB) THAT WERE NOT COMPATIBLE WITH THE AFX SYSTEM PER THE IFU. IT IS UNCLEAR WHETHER THIS CONTRIBUTED TO THE REPORTED EVENT. THE PATIENT'S FINAL STATUS WAS DISCHARGED HOME, BUT THE PATIENT WAS READMITTED ON (B)(6) 2024, WITH SEPSIS AND A URINARY TRACT INFECTION (NON-DEVICE RELATED). NO ADDITIONAL INVESTIGATION OF THIS REPORTED ADVERSE EVENT/INCIDENT IS PLANNED. HOWEVER, SHOULD ADDITIONAL INFORMATION RELEVANT TO THE INVESTIGATION OUTCOME BECOME AVAILABLE, A FOLLOW-UP REPORT WILL BE SUBMITTED. ENDOLOGIX WILL CONTINUE TO MONITOR THIS AND SIMILAR ADVERSE EVENTS/INCIDENTS. DEVICE ITERATION IS AFX2. CORRECTIONS: B2: OUTCOMES ATTRIBUTED TO ADVERSE EVENTS HAS BEEN UPDATED. B5: DESCRIBE EVENT OR PROBLEM HAS BEEN UPDATED. G3: AWARENESS DATE HAS BEEN UPDATED. H6: INVESTIGATION FINDING CODES: REMOVE CODE 3233. H6: INVESTIGATION CONCLUSION CODES: REMOVE CODE 11.
THE PATIENT WAS INITIALLY IMPLANTED WITH AN AFX2 BIFURCATED STENT GRAFT, AFX LIMB STENT GRAFT, AFX VELA SUPRARENAL, AND AN OVATION IX EXTENDER ON (B)(6) 2023, TO TREAT AN ABDOMINAL AORTIC ANEURYSM (AAA). THIS INITIAL PROCEDURE WAS OUTSIDE THE INDICATIONS OF USE (OFF-LABEL) DUE TO THE USE OF ADJUNCTIVE DEVICES NOT COMPATIBLE WITH THE AFX SYSTEM PER THE IFU. ON (B)(6) 2024, DURING A ROUTINE FOLLOW-UP, IT WAS REPORTED THAT THE PATIENT WAS IDENTIFIED WITH AN ENDOLEAK TYPE IIIB. THE PATIENT IS CURRENTLY IN STABLE CONDITION PENDING A RE-INTERVENTION.
THE PATIENT WAS INITIALLY IMPLANTED WITH AN AFX2 BIFURCATED STENT GRAFT, AFX LIMB STENT GRAFT, AFX VELA SUPRARENAL, AND AN OVATION IX EXTENDER ON (B)(6) 2023, TO TREAT AN ABDOMINAL AORTIC ANEURYSM (AAA). THIS INITIAL PROCEDURE WAS OUTSIDE THE INDICATIONS OF USE (OFF-LABEL) DUE TO THE USE OF ADJUNCTIVE DEVICES NOT COMPATIBLE WITH THE AFX SYSTEM PER THE IFU. ON (B)(6) 2024, DURING A ROUTINE FOLLOW-UP, IT WAS REPORTED THAT THE PATIENT WAS IDENTIFIED WITH AN ENDOLEAK TYPE IIIB. THE PATIENT IS CURRENTLY IN STABLE CONDITION PENDING A RE-INTERVENTION. ADDITIONAL INFORMATION: ON (B)(6) 2024, THE PATIENT UNDERWENT A RE-INTERVENTION DURING WHICH THE PHYSICIAN OPTED TO IMPLANT AN AFX2 BIFURCATED STENT GRAFT. THE PATIENT'S FINAL STATUS WAS DISCHARGED HOME, BUT THE PATIENT WAS READMITTED ON (B)(6) 2024, WITH SEPSIS AND A URINARY TRACT INFECTION (NON-DEVICE RELATED).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 756278 | AFX2 | BIFURCATED STENT GRAFT | MIH | ENDOLOGIX | BEA25-100/I16-40 | 2626576-001 | 00818009014726 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 78 YR | Male | Other| R | AFX LIMB STENT GRAFT LOT# 2366387002| AFX VELA SUPRARENAL LOT# 2367788001| OVATION IX EXTENDER LOT# FS060822-37 |